160. Safety and Immunogenicity of Escalating Dose Formulations of High-dose Quadrivalent Influenza Vaccine in Children 6 Months Through < 18 Years of Age

por Chang, Leejah, Anderson, Evan J, Jeanfreau, Robert, He, Ying, Hicks, Bryony, Shrestha, Anju, Pandey, Aseem, Khoury, Rawia, De Bruijn, Iris, Landolfi, Victoria
Publicado 2020

Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial

por Ojeda, Joyce, Arredondo, José Luis, Salcedo, Perla, Paredes-Paredes, Mercedes, Dupuy, Martin, Petit, Celine, Chabanon, Anne Laure, Rivas, Enrique, Gurunathan, Sanjay, De Bruijn, Iris, Pepin, Stephanie
Publicado 2019

Antibody-mediated NK cell activation as a correlate of immunity against influenza infection

por Boudreau, Carolyn M., Burke, John S., Yousif, Ashraf S., Sangesland, Maya, Jastrzebski, Sandra, Verschoor, Chris, Kuchel, George, Lingwood, Daniel, Kleanthous, Harry, De Bruijn, Iris, Landolfi, Victoria, Sridhar, Saranya, Alter, Galit
Publicado 2023

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies

por Liu, Xiaoqiang, Park, Juliana, Xia, Shengli, Liang, Bin, Yang, Shuangmin, Wang, Yanxia, Syrkina, Olga, Lavis, Nathalie, Liu, Shuzhen, Zhao, Chenyan, Ding, Jian, Hu, Jieqiong, Samson, Sandrine I., de Bruijn, Iris A.
Publicado 2022